荟萃分析:胆汁酸螯合剂治疗胆汁酸性腹泻的疗效与安全性
该系统评价与荟萃分析纳入6项随机对照试验共182例经血清、粪便生化参数或75SeHCAT确诊的胆汁酸性腹泻患者,比较胆汁酸螯合剂与安慰剂。平行设计试验的荟萃分析显示,螯合剂在7天平均排便稠度和频率改善≥30%方面均显著优于安慰剂,汇总相对风险分别为1.50(95%CI:1.14-1.96)和2.80(95%CI:1.68-4.67),异质性I2=0%,证据确定性中等,不良事件无统计学显著差异。
要点
- 胆汁酸螯合剂可显著改善胆汁酸性腹泻患者的排便稠度和频率。
- 平行设计试验汇总RR:稠度1.50(95%CI:1.14-1.96),频率2.80(95%CI:1.68-4.67)。
- 不良事件与安慰剂相比无统计学显著差异,耐受性似良好。
核心结论
- 在客观诊断的胆汁酸性腹泻患者中,胆汁酸螯合剂对排便稠度和频率均有显著且快速的改善,且似耐受良好。
研究设计与样本
- 系统评价与荟萃分析,检索数据库自建库至2023年1月8日,最终纳入6项随机对照试验(5项平行设计、1项交叉设计),共182例参与者,评估胆汁酸螯合剂1-8周的效果。
主要发现
- 平行设计试验的荟萃分析显示,螯合剂在7天平均排便稠度改善≥30%方面汇总相对风险为1.50(95%CI:1.14-1.96)。
- 平行设计试验的荟萃分析显示,螯合剂在7天平均排便频率改善≥30%方面汇总相对风险为2.80(95%CI:1.68-4.67)。
- 上述两项分析的异质性均为I2=0%,证据确定性为中等。
- 不良事件方面无统计学显著差异。
关键数值与推荐
- 纳入要求通过血清或粪便生化参数或75SeHCAT明确诊断胆汁酸性腹泻。
- 共同主要终点为7天平均排便稠度和频率改善≥30%。
- 参与者年龄介于第三个至第七个十年,大多为女性。
临床怎么用
- 对于经血清、粪便生化参数或75SeHCAT客观确诊的胆汁酸性腹泻患者,可考虑使用胆汁酸螯合剂以改善排便稠度和频率。
局限性
- 纳入试验仅6项、共182例参与者,样本量有限。
- 一项平行设计和一项交叉设计试验存在偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bile acid diarrhoea, a common cause of diarrhoea-predominant irritable bowel syndrome, has a similar prevalence to coeliac disease and inflammatory bowel diseases. The mainstay of treatment is bile acid sequestrants (BAS). The effectiveness of using bile acid-targeted therapies remains unclear. AIM: To compare BAS with placebo for bile acid diarrhoea. METHODS: We conducted a systematic review and meta-analysis of randomised controlled trials comparing BAS to placebo using a comprehensive search of databases from inception to 8/1/2023. Inclusion required unequivocal diagnosis using serum or faecal biochemical parameters, or 75SeHCAT. Co-primary endpoints were ≥ 30% improvement in bowel movement consistency and frequency averaged over 7 days. Adverse effects were also summarised. RESULTS: Database search resulted in 1152 citations; 1 additional study was added. Ultimately, 6 trials (5 parallel arm, 1 crossover) involving 182 participants evaluated the effectiveness of BAS over 1-8 weeks. Participants were between the third and seventh decades of life and mostly female. The risk of bias was low except in one parallel and one crossover trial. Meta-analysis of parallel-design trials of sequestrants only showed a clinically significant reduction in stool consistency and frequency with pooled relative risks of 1.50 (95% CI: 1.14-1.96) and 2.80 (95% CI: 1.68-4.67), respectively. There was no observable heterogeneity (I2 = 0%), and the certainty of evidence was moderate. There was no statistically significant difference in adverse effects. CONCLUSIONS: This study quantifies the significant and rapid improvement in both stool consistency and frequency with BAS in patients with objective diagnosis of bile acid diarrhoea. Sequestrants also appear well tolerated.
引用
- Dilmaghani S, BouSaba J, Lupianez-Merly C, et al. Meta-Analysis: Efficacy and Safety of Sequestrants for Bile Acid Diarrhoea. Aliment Pharmacol Ther. 2025. PMID: 41090475. doi:10.1111/apt.70390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。